FMS-like tyrosine kinase 3 (FLT3) mutations represent some of the most pivotal genetic alterations in acute myeloid leukemia (AML), influencing ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical ...

China NMPA's Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma's zurletrectinib (ICP-723) ...

New medication appears to be safer and more effective than standard therapy, according to trial led by Chinese and US scientists.

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...